Clinical trials are key to finding new cancer treatments, but with patient participation hovering around 5 percent, new strategies are needed to boost enrollment, particularly to study the rare cancers that have so few cases. One such strategy comes from a new abstract being presented Oct. 28 at the 15th World Conference on Lung Cancer from researchers at Perelman School of Medicine at the University of Pennsylvania studying mesothelioma.
Fuente : http://www.eurekalert.org/pub_releases/2013-10/uop…
Hacer un comentario